BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016;21:333-42. [PMID: 26921288 DOI: 10.1634/theoncologist.2015-0303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Caers J. The Road to a Cure: Emerging Treatments for Multiple Myeloma. Cancers (Basel) 2020;12:E3593. [PMID: 33271749 DOI: 10.3390/cancers12123593] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018;103:1772-84. [PMID: 30171031 DOI: 10.3324/haematol.2018.189159] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
3 Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, Knop S, Wasch R. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica 2018;103:755-8. [PMID: 29712821 DOI: 10.3324/haematol.2018.188516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer 2018;124:2075-85. [PMID: 29409124 DOI: 10.1002/cncr.31243] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
5 Zhang B, Zhou YL, Chen X, Wang Z, Wang Q, Ju F, Ren S, Xu R, Xue Q, Wu Q. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. International Immunopharmacology 2019;68:131-6. [DOI: 10.1016/j.intimp.2018.12.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol 2020;11:762. [PMID: 32457743 DOI: 10.3389/fimmu.2020.00762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
7 Lin Z, Chen X, Li Z, Luo Y, Fang Z, Xu B, Han M. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160485. [PMID: 27483468 DOI: 10.1371/journal.pone.0160485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
8 Fernández de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, Rodríguez-lobato L, Calvo X, Aróstegui JI, Díaz T, Lozano E, Rozman M, Yagüe J, Bladé J, Rosiñol L. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 2018;32:1427-34. [DOI: 10.1038/s41375-018-0013-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
9 Mussetti A, Pellegrinelli A, Cieri N, Garzone G, Dominoni F, Cabras A, Montefusco V. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression. Ann Hematol 2019;98:1713-20. [PMID: 31053880 DOI: 10.1007/s00277-019-03648-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M. Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.. Leuk Lymphoma 2020;61:875-86. [PMID: 31779510 DOI: 10.1080/10428194.2019.1695051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Greil C, Ihorst G, Gaiser F, Salzer U, Bisse E, Kastritis E, Ludwig H, Wäsch R, Engelhardt M. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. Eur J Haematol 2017;99:449-58. [PMID: 28886228 DOI: 10.1111/ejh.12958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Ma J, Cai X, Kang L, Chen S, Liu H. Identification of novel biomarkers and candidate small-molecule drugs in cutaneous melanoma by comprehensive gene microarrays analysis. J Cancer 2021;12:1307-17. [PMID: 33531976 DOI: 10.7150/jca.49702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Singh G. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. J Appl Lab Med 2020;5:1358-71. [PMID: 33150391 DOI: 10.1093/jalm/jfaa153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Rodríguez-lobato LG, Fernández de Larrea C, Cibeira MT, Tovar N, Isola I, Aróstegui JI, Rosiñol L, Díaz T, Lozano E, Yagüe J, Bladé J. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. Amyloid 2017;24:238-45. [DOI: 10.1080/13506129.2017.1390451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Withofs N, Cousin F, De Prijck B, Bonnet C, Hustinx R, Gambhir SS, Beguin Y, Caers J. A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma. Contrast Media Mol Imaging 2017;2017:6162845. [PMID: 29097930 DOI: 10.1155/2017/6162845] [Reference Citation Analysis]
16 Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018;11:10. [PMID: 29338789 DOI: 10.1186/s13045-017-0549-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
17 Heusschen R, Muller J, Duray E, Withofs N, Bolomsky A, Baron F, Beguin Y, Menu E, Ludwig H, Caers J. Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leuk Lymphoma 2018;59:14-28. [PMID: 28573897 DOI: 10.1080/10428194.2017.1323272] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
18 Wichert S, Juliusson G, Johansson Å, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, Hansson M. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS One 2017;12:e0171205. [PMID: 28158311 DOI: 10.1371/journal.pone.0171205] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
19 Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. What Is New in the Treatment of Smoldering Multiple Myeloma? J Clin Med 2021;10:421. [PMID: 33499196 DOI: 10.3390/jcm10030421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Engelhardt M, Ihorst G, Caers J, Günther A, Wäsch R. Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica 2016;101:1276-8. [PMID: 27799344 DOI: 10.3324/haematol.2016.154807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]